Relmapirazin

Relmapirazin
Clinical data
Trade names	Lumitrace
Other names	MB-102
ATC code	V04CH05 (WHO) ;
Identifiers
	IUPAC name (2R)-2-[[3,6-Diamino-5-[[(1R)-1-carboxy-2-hydroxyethyl]carbamoyl]pyrazine-2-carbonyl]amino]-3-hydroxypropanoic acid;
CAS Number	1313706-17-0;
PubChem CID	53389120;
UNII	Q3UQB8PQ6H;
KEGG	D11637;
ChEMBL	ChEMBL1949708;
Chemical and physical data
Formula	C12H16N6O8
Molar mass	372.294 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C([C@H](C(=O)O)NC(=O)C1=C(N=C(C(=N1)N)C(=O)N[C@H](CO)C(=O)O)N)O;
	InChI InChI=1S/C12H16N6O8/c13-7-5(9(21)15-3(1-19)11(23)24)17-8(14)6(18-7)10(22)16-4(2-20)12(25)26/h3-4,19-20H,1-2H2,(H2,14,17)(H2,13,18)(H,15,21)(H,16,22)(H,23,24)(H,25,26)/t3-,4-/m1/s1; Key:XHNJXRDGTITISI-QWWZWVQMSA-N;

Relmapirazin (MB-102) is an investigational fluorescent tracer that is exclusively excreted renally and is used to measure glomerular filtration rate of the kidneys.^[1]^[2]^[3]^[4]^[5]^[6]^[7]

References

^ Dorshow RB, Shieh JJ, Debreczeny MP (17 March 2023). "Clinical results from a pilot multi-center study using a novel fluorescent tracer agent for renal function measurement". In Raghavachari R, Berezin MY (eds.). Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications XIV. p. 19. doi:10.1117/12.2648541. ISBN 978-1-5106-5901-8. S2CID 257614179.
^ Orieux A, Samson C, Pieroni L, Drouin S, Dang Van S, Migeon T, et al. (5 June 2023). "Pulmonary hypertension without heart failure causes cardiorenal syndrome in a porcine model". Scientific Reports. 13 (1): 9130. Bibcode:2023NatSR..13.9130O. doi:10.1038/s41598-023-36124-1. ISSN 2045-2322. PMC 10241877. PMID 37277538.
^ Jang SM, Shieh JJ, Riley IR, Dorshow RB, Mueller BA (July 2023). "Adsorption and Clearance of the Novel Fluorescent Tracer Agent MB-102 During Continuous Renal Replacement Therapy: In Vitro Results". ASAIO Journal. 69 (7): 702–707. doi:10.1097/MAT.0000000000001943. ISSN 1058-2916. PMC 10298171. PMID 37071749.
^ Rosner MH, Sprangers B, Sandhu G, Malyszko J (November 2022). "Glomerular Filtration Rate Measurement and Chemotherapy Dosing". Seminars in Nephrology. 42 (6) 151340. doi:10.1016/j.semnephrol.2023.151340. PMID 37086497. S2CID 258266791.
^ McMahon BA, Rosner MH (February 2020). "GFR Measurement and Chemotherapy Dosing in Patients with Kidney Disease and Cancer". Kidney360. 1 (2): 141–150. doi:10.34067/KID.0000952019. PMC 8809099. PMID 35372903.
^ Schneider AG, Molitoris BA (December 2020). "Real-time glomerular filtration rate: improving sensitivity, accuracy and prognostic value in acute kidney injury". Current Opinion in Critical Care. 26 (6): 549–555. doi:10.1097/MCC.0000000000000770. PMID 33002974. S2CID 222173308.
^ Dorshow RB, Johnson JR, Shieh JJ, Riley IR, Rogers TE, Pino CJ, et al. (July 2023). "Transdermal Detection of MB-102 and Correlation to Meropenem Pharmacokinetics During Continuous Renal Replacement Therapy: In Vivo Results". ASAIO Journal. 69 (7): 708–715. doi:10.1097/MAT.0000000000001945. PMC 10298183. PMID 37097973.

[1] Dorshow RB, Shieh JJ, Debreczeny MP (17 March 2023). "Clinical results from a pilot multi-center study using a novel fluorescent tracer agent for renal function measurement". In Raghavachari R, Berezin MY (eds.). Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications XIV. p. 19. doi:10.1117/12.2648541. ISBN 978-1-5106-5901-8. S2CID 257614179.

[2] Orieux A, Samson C, Pieroni L, Drouin S, Dang Van S, Migeon T, et al. (5 June 2023). "Pulmonary hypertension without heart failure causes cardiorenal syndrome in a porcine model". Scientific Reports. 13 (1): 9130. Bibcode:2023NatSR..13.9130O. doi:10.1038/s41598-023-36124-1. ISSN 2045-2322. PMC 10241877. PMID 37277538.

[3] Jang SM, Shieh JJ, Riley IR, Dorshow RB, Mueller BA (July 2023). "Adsorption and Clearance of the Novel Fluorescent Tracer Agent MB-102 During Continuous Renal Replacement Therapy: In Vitro Results". ASAIO Journal. 69 (7): 702–707. doi:10.1097/MAT.0000000000001943. ISSN 1058-2916. PMC 10298171. PMID 37071749.

[4] Rosner MH, Sprangers B, Sandhu G, Malyszko J (November 2022). "Glomerular Filtration Rate Measurement and Chemotherapy Dosing". Seminars in Nephrology. 42 (6) 151340. doi:10.1016/j.semnephrol.2023.151340. PMID 37086497. S2CID 258266791.

[5] McMahon BA, Rosner MH (February 2020). "GFR Measurement and Chemotherapy Dosing in Patients with Kidney Disease and Cancer". Kidney360. 1 (2): 141–150. doi:10.34067/KID.0000952019. PMC 8809099. PMID 35372903.

[6] Schneider AG, Molitoris BA (December 2020). "Real-time glomerular filtration rate: improving sensitivity, accuracy and prognostic value in acute kidney injury". Current Opinion in Critical Care. 26 (6): 549–555. doi:10.1097/MCC.0000000000000770. PMID 33002974. S2CID 222173308.

[7] Dorshow RB, Johnson JR, Shieh JJ, Riley IR, Rogers TE, Pino CJ, et al. (July 2023). "Transdermal Detection of MB-102 and Correlation to Meropenem Pharmacokinetics During Continuous Renal Replacement Therapy: In Vivo Results". ASAIO Journal. 69 (7): 708–715. doi:10.1097/MAT.0000000000001945. PMC 10298183. PMID 37097973.

[1]

[2]

[3]

[4]

[5]

[6]

[7]